A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

NCT03338426 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension, Dyslipidemia

Interventions

DRUG: Fimasartan 120mg
DRUG: Atorvastatin 40mg
DRUG: Placebo for Fimasartan 120mg
DRUG: Placebo for Atorvastatin 40mg

Sponsor

Boryung Pharmaceutical Co., Ltd